Angelica keiskei extract and application thereof

The Asahi leaf extract is prepared by ethanol solution extraction and n-butanol extraction, combining grape seed extract and tomato red microcapsules to form a suitable anti-aging composition, which solves the complex and costly preparation of Asahi leaf extract in the prior art. The problem of this problem has achieved low cost, large-scale application and significant anti-aging effects of Asahi leaf extract.

CN119014538APending Publication Date: 2024-11-26SHIJIAZHUANG YILING PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310593750.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-24
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The preparation process of existing Asahi leaf extracts is complex and costly, and it is difficult to apply on a large scale. Fresh products are subject to seasonal and logistics restrictions, making them difficult to apply on a long-term and large scale basis. The existing compounds are expensive and are not suitable for middle- and low-income people.

Method used

The Akira leaf extract is prepared by ethanol solution extraction, n-butanol extraction and vacuum oven drying, containing chlorogenic acid, hypericin and luteolin, forming a suitable mass percentage ratio, and is prepared as capsules and powders. Isoform, composition combining grape seed extract and tomato red microcapsules.

Benefits of technology

It has achieved low cost and easy to apply in large-scale applications of Asahi leaf extract, with significant anti-natural aging effects, improved cognitive function, muscle strength, cardiac function and cerebral blood flow and other indicators, and is suitable for the pharmaceutical and food fields.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_6
    Figure SMS_6
Patent Text Reader

Abstract

The invention relates to an angelica keiskei extract and application thereof. The angelica keiskei extract is prepared from chlorogenic acid, hyperoside and galuteolin. The angelica keiskei extract provided by the invention has an anti-aging effect and has a good application prospect in products for resisting natural aging.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medicine and food, and in particular to an Angelica keiskei leaf extract and application thereof. Background Art

[0002] Aging refers to the overall phenomenon of the gradual decline of the body's structure, metabolism and adaptability. There are many manifestations of human aging, including the decline of cognitive function, weakening of muscle strength, decline of heart function, hair loss, etc., which seriously affect the patient's quality of life.

[0003] Angelica kei is a perennial herb of the Apiaceae family native to Japan. It has been used as a food ingredient in Japan, South Korea and other places. There is information showing that some parts of my country have begun to introduce Angelica kei since 2008, and it is now planted in many provinces such as Shandong, Hainan, Jiangsu, Sichuan, Guizhou, Yunnan, Guangdong, and Liaoning. People usually use its tender stems and leaves for salad dressing, stir-frying, juicing, boiling soup, or frying tea or dry grinding. The National Health Commission's Announcement No. 2 of 2019 lists the stems and leaves of Angelica kei as new food ingredients. The recommended consumption of fresh products is ≤50 grams / day, and the recommended consumption of dry products is converted to fresh products.

[0004] Existing technologies show that tomorrow leaf can improve muscle atrophy caused by cancer and aging, increase bone density, improve joint flexion and extension, etc. Tomorrow leaf and its extract have the pharmacological effect of delaying aging, among which the natural compound 4,4′-dimethoxychalcone extracted and separated has anti-aging properties.

[0005] Although Angelica keiskei has multiple effects such as anti-aging, the effects of Angelica keiskei have not been fully applied at present. On the one hand, the fresh food Angelica keiskei needs to go through a relatively complicated production process and be cooked, which is not suitable for people with a fast pace of life. And fresh food is limited by factors such as season and logistics, and it is difficult to apply it on a long-term and large scale. On the other hand, although the compounds separated and proposed in the prior art show effects such as anti-aging, the products prepared by this method are expensive, unfriendly to middle- and low-income people, and difficult to apply on a large scale.

[0006] Chinese patent CN112674336A discloses an antioxidant composition and an antioxidant health food, wherein the antioxidant composition comprises Angelica keiskei extract, grape seed extract and tomato red. The Angelica keiskei extract contained in the composition is obtained by reflux extraction of Angelica keiskei with water, and is a water-soluble extract. Although it exhibits a certain antioxidant effect (see comparative example 4 in Table 3 on page 10 of the specification), the effect is limited and it is not suitable for use alone. Summary of the invention

[0007] In order to solve one of the above technical problems existing in the prior art, the present invention provides an Angelica keiskei extract and its application. The Angelica keiskei extract of the present invention has the effect of resisting natural aging.

[0008] In a first aspect, the present invention provides an Angelica keiskei leaf extract comprising chlorogenic acid, hyperoside and olibanum.

[0009] In some embodiments, the content of chlorogenic acid is 2.5% to 4.5% by mass, for example, 2.5%, 2.8%, 3.0%, 3.5%, 4.0% or 4.5%.

[0010] In some embodiments, the content of hyperoside is 0.5% to 3.5% by mass, for example, 0.5%, 1.0%, 1.4%, 1.8%, 2.3%, 2.6%, 2.9%, 3.2% or 3.5%.

[0011] In some embodiments, the content of luteolin is 2.0% to 5.0% by mass, for example, 2.0%, 2.2%, 2.4%, 2.6%, 2.8%, 3.2%, 3.4%, 3.8%, 4.2%, 4.6% or 5.0%.

[0012] In some embodiments, the Angelica keiskei extract further comprises 4-hydroxyderesin, yellow angelica alcohol, etc. In terms of mass percentage, the content of 4-hydroxyderesin is 0.1% to 0.5%, for example, 0.1%, 0.13%, 0.16%, 0.19%, 0.22%, 0.25%, 0.30%, 0.35%, 0.40%, 0.45% or 0.5%.

[0013] In some embodiments, the content of yellow angelica alcohol is 0.4% to 1.0% by mass, such as 0.4%, 0.44%, 0.48%, 0.52%, 0.56%, 0.60%, 0.65%, 0.70%, 0.75%, 0.85% or 1.0%. In some embodiments, the content of chlorogenic acid is 3.4% to 3.8%, the content of hyperoside is 1.8% to 2.2%, the content of luteolin is 3.6% to 4.2%, the content of 4-hydroxydersin is 0.38% to 0.42%, and the content of yellow angelica alcohol is 0.7% to 0.9%.

[0014] In some embodiments, the Angelica keiskei extract is obtained by a preparation method comprising the following steps:

[0015] (1) extracting Angelica keiskei with an ethanol solution to obtain an ethanol extract;

[0016] (2) recovering ethanol from the ethanol extract and concentrating the extract to obtain a concentrated solution;

[0017] (3) extracting the concentrated solution with n-butanol to obtain an n-butanol extract.

[0018] In some embodiments, the preparation method further comprises: (4) recovering the n-butanol from the n-butanol extract and concentrating under reduced pressure to obtain an extract.

[0019] In some embodiments, the preparation method further comprises: (5) drying the extract to obtain a dry extract.

[0020] In some embodiments, the preparation method further comprises: (6) crushing the dry paste to obtain dry paste powder.

[0021] In some embodiments, in step (1), the volume concentration of the ethanol solution is 55-65%, preferably 58-62%, and more preferably 60%.

[0022] In some embodiments, in step (1), the extraction temperature is such that the ethanol aqueous solution is in a reflux state.

[0023] In some embodiments, in step (1), the extraction is performed 1-5 times, preferably 2-3 times.

[0024] In some embodiments, in step (1), the time for each extraction is 1-3 hours, preferably 1-2 hours, and more preferably 1.5 hours.

[0025] In some embodiments, in step (1), during each extraction, the mass volume ratio of Angelica keiskei to the ethanol aqueous solution used is 1:5-1:15 (g / mL), more preferably 1:10 (g / mL).

[0026] In some embodiments, in step (2), the content of Angelica keiskei in the concentrated solution is 0.5-2 g / ml of the concentrated solution, preferably 0.8-1.2 g / ml of the concentrated solution.

[0027] In some embodiments, the extraction is performed 1-5 times, preferably 2-4 times, and more preferably 3 times.

[0028] In some embodiments, in step (3), the volume of n-butanol used for each extraction is 0.5-3 times, preferably 1-1.5 times, the volume of the concentrated solution.

[0029] In some embodiments, in step (4), the volume of n-butanol used for each extraction is 0.5-3 times, preferably 1-1.5 times, the volume of the concentrated solution.

[0030] In some embodiments, in step (4), the reduced pressure concentration includes first reducing the pressure of the extract to recover n-butanol, and then reducing the pressure to concentrate at a temperature of 40° C. to 80° C. and a vacuum degree of 0.04 to 0.09 MPa.

[0031] In some embodiments, in step (4), the density of the extract is measured at 60°C to be a relative density of 1.20 to 1.30. The drying method of the present invention can be vacuum oven drying, spray drying and vacuum belt drying. In some embodiments, in step (5), the extract is dried by vacuum oven drying at a drying temperature of 60 to 70°C and a vacuum degree of 0.04 to 0.1 MPa, preferably 0.04-0.08 MPa; the moisture content of the dry paste is controlled to be ≤5%.

[0032] In some embodiments, in step (6), the mesh size of the sieve when the dry paste is crushed and sieved is 80 mesh.

[0033] In some embodiments, the preparation method of the Angelica keiskei extract specifically comprises the following steps:

[0034] a. Place the tomorrow leaf in an extraction tank, add 60% ethanol solution, boil and reflux for 1.5 hours, filter, collect the filtrate, and set aside the residue;

[0035] b. Add 60% ethanol solution to the residue obtained in step a, boil and reflux for 1.5 hours, filter, collect the filtrate and set aside;

[0036] c. The filtrate obtained in step a is combined with the filtrate obtained in step b, and the ethanol is recovered under reduced pressure and concentrated to prepare a concentrated solution for standby use;

[0037] d. Add n-butanol to the concentrated solution obtained in step c for extraction, collect the n-butanol extract, extract three times in total, and combine the n-butanol extracts;

[0038] e. The combined extracts in step d were first decompressed to recover n-butanol, and then concentrated under reduced pressure at a temperature of 40 ℃ to 80 ℃ and a vacuum degree of 0.04 to 0.09 MPa to a relative density of 1.20 to 1.30, measured at 60 ℃ to obtain an extract;

[0039] f. The extract prepared in step e is dried to obtain a dry paste, which is crushed and sieved to obtain an extract of Angelica keiskei.

[0040] In a second aspect, the present invention also provides the use of the Angelica keiskei extract as described in the first aspect in the preparation of food for fighting natural aging. In some embodiments, the food includes ordinary food and health food, and the dosage form of the health food includes capsules, powders, granules, tablets, and suspensions.

[0041] In a third aspect, the present invention also provides the use of the Angelica keiskei extract as described in the first aspect in preparing a composition for fighting natural aging. In some embodiments, the composition is a composition containing Angelica keiskei extract, grape seed extract, and tomato red microcapsules, and the dosage form of the composition includes capsules, powders, granules, tablets, and suspensions.

[0042] In some embodiments, the preparation method of the composition containing Angelica keiskei extract, grape seed extract, and lycopene microcapsules includes: a. placing Angelica keiskei extract, grape seed extract, and corn starch in a mixer, adjusting the rotation speed to 6-15 rpm, for example, 8 rpm, and mixing for, for example, 30 minutes to obtain a mixed powder; b. dry granulating the mixed powder obtained in step a, setting the main pressure to 6-10 MPa, passing through a 14-mesh sieve, collecting the particles for later use; c. placing the particles obtained in step b, lycopene microcapsules, and magnesium stearate in a mixer, rotating at a speed of 6-15 rpm, for example, 8 rpm, and mixing for, for example, 20 minutes to obtain total mixed particles for later use; d. filling capsules with the total mixed particles prepared in step c.

[0043] In some embodiments, the natural aging is manifested as a decline in cognitive function, and / or a decline in muscle strength, and / or a decline in energy metabolism function, and / or a decline in cardiac function, and / or a decline in cerebral blood flow indicators, and / or an increase in frailty index, and / or a decline in hair, and / or an increase in organ coefficients.

[0044] In some embodiments, the natural aging is manifested as a decline in cardiac function.

[0045] The Angelica keiskei n-butanol extract provided by the invention has the effect of resisting natural aging and can be applied to the fields of medicine, food (such as ordinary food and health food). DETAILED DESCRIPTION

[0046] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The specific embodiments described herein are only used to explain the present invention and are not intended to constitute any limitation to the present invention.

[0047] The Angelica keiskei extract provided by the present invention is an Angelica keiskei n-butanol extract, and the Angelica keiskei raw material used to prepare the extract is a dry product of Angelica keiskei stems and leaves that complies with the provisions of "Announcement No. 2 of the National Health Commission in 2019".

[0048] Example 1 Preparation of Angelica keiskei n-butanol extract

[0049] 4000 g of Angelica keiskei raw material was placed in an extraction tank, 60000 mL of 60% ethanol solution was added, and the mixture was boiled and refluxed for 1.5 hours. The extract was filtered and the filtrate was collected.

[0050] In the same manner, 40000 mL of 60% ethanol solution was added to the filter residue, and the reflux extraction was repeated once, and the filtrate was filtered to obtain the filtrate.

[0051] The two filtrates were combined, ethanol was recovered under reduced pressure and concentrated to a volume of 4000 mL to obtain a concentrated solution for standby use.

[0052] An equal volume of n-butanol was added to the concentrate for extraction, and the n-butanol extracts were collected. The extractions were performed for 3 times in total, and the n-butanol extracts were combined.

[0053] The combined extracts are firstly subjected to reduced pressure to recover n-butanol, and then concentrated under reduced pressure at a temperature of 40°C-80°C and a vacuum degree of 0.04-0.09 MPa to a relative density of 1.21 (measured at 60°C) to obtain an extract.

[0054] The extract was dried in a vacuum oven (drying temperature 60°C, vacuum degree 0.07 MPa) to prepare a dry paste (the moisture content of the dry paste was controlled within 5%), and finally 192.4 g of dry paste was obtained, with a paste yield of 4.81%, and each gram of dry paste contained 20.79 g / g of tomorrow leaf crude drug.

[0055] The dry paste was crushed and sieved (sieve mesh number: 80 mesh) to obtain dry paste powder (brown-green powder).

[0056] Example 2 Preparation of Angelica keiskei n-butanol extract capsules

[0057] The capsule can be prepared from the Angelica keiskei n-butanol extract according to a conventional method.

[0058] Example 3 Preparation of capsules containing the composition of Angelica keiskei n-butanol extract

[0059] The formulated amount of Angelica keiskei n-butanol extract, grape seed extract and corn starch were placed in a mixer, the speed was adjusted to 8 rpm, and the mixture was mixed for 30 minutes to obtain a mixed powder.

[0060] The mixed powder is dry granulated, the main pressure is set to 6-10MPa, and the particles are collected through a 14-mesh sieve for later use.

[0061] The granules obtained by granulation, lycopene microcapsules and magnesium stearate were placed in a mixer at a speed of 8 rpm and mixed for 20 minutes to obtain total mixed granules.

[0062] The total mixed granules and the gelatin hollow capsules are placed in a fully automatic capsule filling machine, and the capsules are filled to control the weight of the content of each capsule to be 0.5 g ± 5%.

[0063] Comparative Example 1 Preparation of Angelica keiskei ethyl acetate extract

[0064] Take 4000 g of Angelica keiskei raw material, pour it into an extraction tank, add 40000 mL of 60% ethanol solution by volume, boil and reflux for 1.5 hours, filter the extract and collect the filtrate.

[0065] In the same manner, 40000 mL of 60% ethanol solution was added to the filter residue, and the reflux extraction was repeated once, and the filtrate was filtered to obtain the filtrate.

[0066] The two filtrates were combined and concentrated under reduced pressure to a volume of 4000 mL to obtain a concentrated solution for standby use.

[0067] An equal volume of ethyl acetate was added to the concentrate for extraction, and the ethyl acetate extracts were collected. The extraction was performed 3 times in total, and the ethyl acetate extracts were combined.

[0068] The combined extracts are first decompressed to recover ethyl acetate, and then decompressed and concentrated at a temperature of 40°C-80°C and a vacuum degree of 0.04-0.09Mpa to a relative density of 1.15-1.25 (measured at 60°C) to obtain an extract.

[0069] The extract was dried in a vacuum oven (drying temperature 60°C, vacuum degree 0.07 MPa) to prepare a soft paste, and finally 47.6 g of the soft paste was obtained, with an extract yield of 1.19%, and each gram of the paste contained 84.03 g / g of Angelica keiskei crude drug.

[0070] The components of the n-butanol extract prepared in Example 1 and the ethyl acetate extract prepared in Comparative Example 1 were tested, and the results are shown in the following table:

[0071]

[0072]

[0073] Application Example 1 Pharmacological Activity Experiment of Angelica keiskei n-butanol Extract

[0074] In order to investigate the pharmacological activity of Angelica keiskei n-butanol extract, the inventors conducted an anti-aging experiment on mice. While investigating the anti-aging activity of Angelica keiskei n-butanol extract, they also investigated the anti-aging activity of Angelica keiskei ethyl acetate extract and compared the results.

[0075] The anti-aging experiment was conducted on naturally aged mice, and the n-butanol extract of Angelica keiskei and the ethyl acetate extract of Angelica keiskei were investigated in low-dose and high-dose groups, respectively, as follows.

[0076] 1.1 Test sample

[0077] ① Angelica keiskei n-butanol extract: a dry paste powder prepared according to Example 1.

[0078] ②Ethyl acetate extract of Angelica keiskei Koidzumi: The soft paste prepared according to Comparative Example 1.

[0079] 1.2 Tool drugs, main reagents and materials

[0080] 10% Neutral formalin fixative: Beijing Yili Fine Chemicals Co., Ltd., batch number: 20220108, validity period 12 months.

[0081] 1.3 Experimental system

[0082] 1.3.1 Animal strain: BALB / c mice.

[0083] 1.3.2 Animal level: SPF level.

[0084] 1.3.3 Animal gender and quantity: 45, female.

[0085] 1.3.4 Animal age at the start of dosing: Approximately 17 - 18 months old in actuality.

[0086] 1.3.5 Animal weight at the start of dosing: 25 - 35 g.

[0087] 1.3.6 Animal source: Purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd.

[0088] 1.3.7 Breeding conditions: Mice were caged and raised in the New Drug Evaluation Center of Hebei Yiling Pharmaceutical Research Institute Co., Ltd. The light was 12 hours per day, the temperature was 20 - 26 °C, and the relative humidity was 40 - 70%. The experimental animal use license number: SYXK(Hebei)2020 - 003.

[0089] 1.3.8 General observation: Observe the drinking water, food intake and health status of the animals, as well as the signs of disease and death.

[0090] 1.3.9 Feed: SPF mouse and rat maintenance feed, provided by Beijing Huafukang Biotechnology Co., Ltd., feed batch numbers: 2110251203, 2110251223, 2210250208, license number: SCXK(Beijing)2019 - 0008. Medicated feed, provided by Jiangsu Xietong Pharmaceutical Biotechnology Co., Ltd., feed batch numbers: 20211125, 20220120, license number: Su Feed License(2019)01008.

[0091] 1.3.10 Drinking water: Drink the purified water prepared by the ROA50 experimental animal drinking water system (instrument number YL - LE - A01). The drinking water bottles were filled for free drinking, and the water quality was tested to meet the "Sanitary Standard for Drinking Water".

[0092] 1.3.11 Bedding: Ordinary grade corn cob bedding, which shall be sterilized at high temperature and high pressure before use. It is provided by Beijing Keao Xieli Feed Co., Ltd. Bedding batch numbers: 21129811, 22019811, 22049811, license number: SCXK(Beijing)2020-0010.

[0093] 1.3.12 Identification: The experimental animals shall be marked with ear tags.

[0094] 1.4 Instrument system

[0095] Mettler ME104E analytical balance (YL-LE-B045), METTLER TOLEDO.

[0096] DT2000 electronic balance (YL-LE-B045), Changshu Shuangjie Testing Instrument Factory.

[0097] Barnes maze (YL-LE-A62), Shanghai Jiliang Software Technology Co., Ltd.

[0098] Small animal energy metabolism monitoring system (YL-LE-B045), Beijing Tiansi Yida Technology Co., Ltd.

[0099] VEVO 3100LT Small Animal Ultrasound System (YL-LE-A085), FUJIFILM VisualSonics, Inc.

[0100] 2 Test methods

[0101] 2.1 Experimental design basis

[0102] 2.1.1 Design basis: relevant literature.

[0103] 2.1.2 Experimental system selection instructions

[0104] In this experiment, naturally aged mice were selected to simulate the natural aging process of humans and to study the anti-aging effects of the test products.

[0105] 2.2 Dosage and grouping

[0106] According to relevant literature and previous experimental studies, the low and high doses of Angelica keiskei n-butanol extract (ZDC) and Angelica keiskei ethyl acetate extract (YSYZ) were 10.96 / 21.92 g crude drug / kg, respectively. 45 BALB / c mice were divided into 5 groups according to the Barnes maze data, namely, model control group, ZDC low-dose group, ZDC high-dose group, YSYZ low-dose group, and YSYZ high-dose group, as shown in Table 1.

[0107] Table 1

[0108]

[0109] 2.3 Method of test article administration

[0110] Add to customized feed, consistent with intended route of use.

[0111] 2.4 Feed preparation and storage

[0112] According to the setting of the corresponding dosage for each group of mice, calculate the concentration of feed preparation, and calculate the amount of test sample required based on the number of animals and the amount of food intake of animals, and mix it evenly in the feed. The prepared feed is stored at room temperature for use.

[0113] 2.5 Administration of test articles

[0114] The test articles were orally administered via feed, the animals in the model control group were given SPF mouse and rat maintenance feed, and the animals in other groups were given feed prepared with the corresponding test articles for 14 consecutive weeks.

[0115] 2.6 Instrument system

[0116] Mettler ME104E analytical balance (YL-LE-B045), METTLER TOLEDO.

[0117] DT2000 electronic balance (YL-LE-B045), Changshu Shuangjie Testing Instrument Factory.

[0118] Barnes maze (YL-LE-A62), Shanghai Jiliang Software Technology Co., Ltd.

[0119] Small animal energy metabolism monitoring system (YL-LE-B045), Beijing Tiansi Yida Technology Co., Ltd.

[0120] VEVO 3100LT Small Animal Ultrasound System (YL-LE-A085), FUJIFILM VisualSonics, Inc.

[0121] 2.7 Statistical methods

[0122] The experimental data were analyzed and processed using SPSS20.0 statistical software, with the test level of 0.05 and 0.01. The results were expressed as mean ± standard deviation It indicates that a normality test was performed first. For data that conformed to the normal distribution, one-way analysis of variance (One-Way ANOVA) was used to compare the means. If the variances were equal, the least significant difference (LSD) method was used for pairwise comparisons. If the variances were unequal, Dunnett's T3 test was used for pairwise comparisons. If the data did not conform to the normal distribution, a nonparametric test was used. The chi-square test or rank sum test was used for count data.

[0123] 2.7 Observation indicators

[0124] 2.7.1 Cognitive Function

[0125] Learning and memory ability (Barnes maze): Detect the spatial learning and memory ability of animals. Before the test, a blue background cloth was laid flat on the operating table to ensure that the background color was distinguished from the color of the mouse. At the beginning of the adaptive training, the mouse was placed in the center of the maze to adapt for 10 seconds, and then the mouse was guided into the target box, where it stayed for 10 seconds, and then guided into the box again, for a total of 3 times. During the test, the detection software was turned on for video acquisition, and the mouse was restricted to move in the light-proof box for 6 seconds. The light-proof box was removed and the timing started at the same time. When all four limbs of the mouse entered the target box (the target box was equipped with a dark area and steps to make it easy for the mouse to avoid), it was counted as one successful avoidance, and the mouse stayed in the target box for 3 seconds. Each mouse was observed for 3 minutes each time. At the interval between the tests of two mice, the maze area and the target box were wiped with 75% alcohol (to prevent the mouse from relying on smell rather than memory to determine the location of the target box). The mice were trained once a day for 3 consecutive days. On the 4th day, the learning and memory ability was formally tested, and on the 11th day, the long-term memory ability was tested. The software was used to collect parameters such as latency, total distance, and total time for statistical analysis. The mice were measured before administration, and after 6 and 12 weeks of administration.

[0126] (1) Short-term memory

[0127] ① Before administration: Compared with the model control group, there was no statistical difference in the incubation period, total time and total distance of each group.

[0128] ② After 6 weeks of administration: compared with the model control group, there was no statistical difference in the incubation period, total time and total distance of each group.

[0129] ③Administer for 12 weeks:

[0130] Incubation period: Compared with the model control group, the incubation period of the low-dose ZDC group was significantly reduced (P < 0.05), and the incubation period of the high-dose ZDC group was significantly reduced (P < 0.01), as shown in Table 2.

[0131] Total time: Compared with the model control group, the total time of the low-dose and high-dose ZDC groups was significantly reduced (P < 0.05), as shown in Table 3.

[0132] Total distance: Compared with the model control group, the total distance in the ZDC high-dose group was significantly reduced (P < 0.05), as shown in Table 4.

[0133] Table 2 Short-term memory (Barnes maze) of mice in each group - latency (s)

[0134]

[0135]

[0136] Compared with the model control group, *P<0.05, **P<0.01.

[0137] Table 3 Short-term memory (Barnes maze) of mice in each group-total time (s)

[0138]

[0139] Compared with the model control group, *P<0.05, **P<0.01.

[0140] Table 4 Short-term memory (Barnes maze) of mice in each group-total distance (mm)

[0141]

[0142] Compared with the model control group, *P<0.05, **P<0.01.

[0143] (2) Long-term memory

[0144] ①Administer for 6 weeks:

[0145] Incubation period: Compared with the model control group, the incubation period of the high-dose ZDC group was significantly reduced (P < 0.05), as shown in Table 5. Total time: Compared with the model control group, there was no statistical difference among the groups, as shown in Table 6.

[0146] Total distance: Compared with the model control group, there was no statistical difference among the groups, as shown in Table 7.

[0147] ②Administer the drug for 12 weeks:

[0148] Latent period: Compared with the model control group, the latent period of the ZDC high-dose group was significantly reduced (P < 0.05). As shown in Table 5. Total time: Compared with the model control group, the total time of the ZDC high-dose group was significantly reduced (P < 0.05). As shown in Table 6. Total distance: Compared with the model control group, the total distance of the ZDC high-dose group was significantly reduced (P < 0.05). As shown in Table 7.

[0149] Table 5 Long-term memory (Barnes maze) of mice in each group - latency (s)

[0150]

[0151] Compared with the model control group, *P<0.05, **P<0.01.

[0152] Table 6 Long-term memory (Barnes maze) of mice in each group-total time (s)

[0153]

[0154] Compared with the model control group, *P<0.05, **P<0.01.

[0155] Table 7 Long-term memory (Barnes maze) of mice in each group-total distance (mm)

[0156]

[0157] Compared with the model control group, *P<0.05, **P<0.01.

[0158] 2.7.2 Muscle strength

[0159] (1) Muscle endurance (hanging test): Place mice on a hanging net (specification: 3 mesh, 40 cm diameter, Shanghai Yanjin Screen Processing Factory). After their limbs grasp the net firmly, invert the hanging net at a height of 1 meter and start timing at the same time to record the time it takes for each mouse to land. Measure 3 times and take the average value. Measure before administration and 4, 8, and 12 weeks after administration.

[0160] The results of the hanging time are shown in Table 8.

[0161] Before drug administration, there was no statistical difference in the hanging time among the groups.

[0162] After 4 weeks of administration, there was no statistical difference in the suspension time among the groups.

[0163] After 8 weeks of administration, the suspension time in the high-dose ZDC group was significantly increased compared with the model control group (P<0.05).

[0164] After 12 weeks of administration, the suspension time in the low-dose and high-dose ZDC groups was significantly increased compared with the model control group (P<0.05).

[0165] Table 8 Hanging time of mice in each group (s)

[0166]

[0167] Compared with the model control group, *P<0.05, **P<0.01.

[0168] (2) Forelimb muscle strength (grip strength test): After the grip strength tester is calibrated, set the strength unit KGF. Place the mouse on the grip strength test net and slowly pull the mouse backwards to ensure that the mouse is parallel to the test net. Wait until its front paws are out of the grip strength test net and record the strength on the display. Test three times and take the maximum value. Measure once after 12 weeks of administration.

[0169] The grip results are shown in Table 9.

[0170] After 12 weeks of administration, the gripping force in the low-dose and high-dose ZDC groups was significantly increased compared with the model control group (P<0.05).

[0171] Table 9 Grip strength (KGF) of mice in each group

[0172]

[0173]

[0174] Compared with the model control group, *P<0.05, **P<0.01.

[0175] 2.7.3 Energy metabolism

[0176] The small animal energy metabolism monitoring system was used to monitor the changes in energy metabolism of mice. After 12 weeks of administration, the mice were placed in the energy metabolism chamber and adapted for 2 days. On the third day, the animals' 24-hour oxygen consumption, carbon dioxide production, respiratory exchange rate, heat and other indicators were formally monitored.

[0177] The main statistics were the average values ​​of 24-hour oxygen consumption, carbon dioxide production, respiratory exchange rate, and heat production. The results are shown in Table 10.

[0178] Average oxygen consumption (VO 2 ): Compared with the model control group, the average oxygen consumption in the high-dose ZDC group was significantly increased (P<0.01).

[0179] Average carbon dioxide production (VCO 2 ): Compared with the model control group, the carbon dioxide production in the high-dose ZDC group was significantly increased (P<0.01).

[0180] Average respiratory exchange ratio (RER): Compared with the model control group, there was no statistical difference among the groups.

[0181] Average heat production (H): Compared with the model control group, the average heat production in the high-dose ZDC group was significantly increased (P < 0.01).

[0182] Table 10 Energy metabolism of mice in each group

[0183]

[0184] Compared with the model control group, *P<0.05, **P<0.01.

[0185] 2.7.4 Heart function

[0186] After 12 weeks of administration, the cardiac function of the mice was detected using a small animal ultrasound system.

[0187] Mice were anesthetized with 2.5% isoflurane and fixed in a supine position on a physiological monitoring platform. Electrocardiogram, respiration and body temperature were monitored, and anesthesia was maintained with 1% isoflurane. Lubricating ointment was applied to the eyes of the mice to prevent dryness of the eyes, chest hair was removed, and ultrasound gel was applied to the chest. A linear array transducer (MX400) with a center frequency of 30 MHz was used to collect long-axis images of the left ventricle of the heart in M ​​mode and B mode, and software was used to analyze indicators such as left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS).

[0188] The cardiac function results of mice in each group are shown in Table 11.

[0189] Left ventricular ejection fraction (LVEF): Compared with the model control group, the LVEF in the YSYZ low-dose group was significantly increased (P < 0.01), and the LVEF in the ZDC low-dose and high-dose groups was significantly increased (P < 0.05).

[0190] Left ventricular fractional shortening (LVFS): Compared with the model control group, LVFS in the YSYZ low-dose group, ZDC low-dose group, and ZDC high-dose group were significantly increased (P<0.05).

[0191] Table 11 Cardiac function of mice in each group

[0192] Group LVEF (%) LVFS(%) Model control group 78.72±10.21 47.69±10.48 YSYZ low dose group 93.56±7.24** 69.55±13.97* YSYZ high dose group 83.34±7.17 51.66±8.27 ZDC low dose group 89.05±8.92* 60.01±11.42* ZDC high dose group 92.80±7.46* 66.31±10.64*

[0193] Compared with the model control group, *P<0.05, **P<0.01.

[0194] 2.7.5 Cerebral blood flow

[0195] After 12 weeks of drug administration, the cerebral blood flow of mice was detected using a small animal ultrasound system.

[0196] Mice were anesthetized with 2.5% isoflurane and fixed in a prone position on a physiological monitoring platform. Electrocardiogram, respiration and body temperature were monitored, and anesthesia was maintained with 1% isoflurane. Lubricating ointment was applied to the eyes of the mice to prevent dryness of the eyes, the hair on the head was shaved, and ultrasound gel preheated to 37°C was applied to the head. A linear array transducer (MX400) with a center frequency of 30MHz was used to obtain the blood flow of the middle cerebral artery, posterior communicating artery, and posterior artery of the mice in pulsed Doppler mode. The sample volume (Sample Volume, SVgate) was 0.34, the PRF (Pulse repetition frequency) value was 10 Hz, and the mean value of the three arteries was measured. If repeated acquisition was not possible, the blood flow of the artery was counted as 0. The software was used to analyze cerebral blood flow indicators such as mean blood velocity (mean velocity, meanvel), time velocity integral (VTI), peak systolic velocity (PSV), and end diastolic velocity (EDV).

[0197] The cerebral blood flow results of each group of mice are shown in Table 12.

[0198] End-systolic blood flow velocity (PSV): Compared with the model control group, the end-systolic cerebral blood flow in the YSYZ low-dose group, YSYZ high-dose group, and ZDC low-dose group was significantly increased (P < 0.05), and the end-systolic cerebral blood flow in the ZDC high-dose group was significantly increased (P < 0.01).

[0199] End-diastolic blood flow velocity (EDV): Compared with the model control group, the end-diastolic cerebral blood flow in the low-dose ZDC group was significantly increased (P < 0.05), and the end-diastolic cerebral blood flow in the high-dose ZDC group was significantly increased (P < 0.01).

[0200] Mean blood velocity (Mean Vel): Compared with the model control group, the mean blood velocity in the YSYZ high-dose group and the ZDC low-dose group was significantly increased (P < 0.05), and the mean blood velocity in the ZDC high-dose group was significantly increased (P < 0.01).

[0201] Time velocity integral (VTI): Compared with the model control group, the time velocity integral of the YSYZ high-dose group and the ZDC low-dose group was significantly increased (P < 0.05), and the time velocity integral of the ZDC high-dose group was significantly increased (P < 0.01).

[0202] Table 12 Cerebral blood flow of mice in each group

[0203]

[0204] Compared with the model control group, *P<0.05, **P<0.01.

[0205] 2.7.6 Frailty Index

[0206] After 12 weeks of administration, the frailty index was measured in mice. The weight, body temperature, hair loss, loss of fur color, dermatitis, loss of whiskers, fur condition, tumors, abdominal distension, kyphosis, stiff tail, gait disorder, tremor, forelimb grip, body condition core, vestibular disorder, hearing loss, cataract, corneal volume, swelling of eye secretions, microphthalmia, decreased vision, threat reflex, runny nose, malocclusion, rectal prolapse, vaginal uterine penile prolapse, diarrhea, respiratory rate depth, mouse expression level, piloerection and other physiological indicators were observed. Except for weight and body temperature, which were scored as 0, 0.25, 0.5 and 1 in different intervals, the rest were scored as 0, 0.5 and 1 according to severity. The average of the 31 items was taken as the frailty index.

[0207] The results of the weakness index of each group of mice are shown in Table 13.

[0208] Compared with the model control group, the frailty index of the high-dose YSYZ group and the high-dose ZDC group was significantly reduced (P<0.05).

[0209] Table 13 Weakness index of mice in each group

[0210] Group FI Model control group 0.23±0.07 YSYZ low dose group 0.21±0.02 YSYZ high dose group 0.19±0.03* ZDC low dose group 0.20±0.01 ZDC high dose group 0.19±0.05*

[0211] Compared with the model control group, *P<0.05, **P<0.01.

[0212] 2.7.7 Hair

[0213] The hair of the animals was observed and scored according to the degree of hair loss in the frailty index, i.e., 0 point - no hair loss, 0.5 point - hair loss area less than 25%, 1 point - hair loss area greater than 25%, and then statistical analysis was performed.

[0214] The results of hair scoring of mice in each group are shown in Table 14.

[0215] Compared with the model control group, the hair score in the high-dose ZDC group was significantly reduced (P<0.05).

[0216] Table 14 Hair scores of mice in each group

[0217]

[0218] Compared with the model control group, *P<0.05, **P<0.01.

[0219] 2.7.8 Organ indicators

[0220] After removing the eyeballs of mice and taking blood, the brain, fat, heart, lungs, liver, spleen, pancreas, adrenal glands, kidneys, ovaries, uterus, etc. were taken. The weight of the heart, lungs, liver, kidneys, and brain was weighed, and the organ coefficient was calculated. Some organs were fixed with 10% neutral formalin buffer and sent for pathological examination. The tissue sections were stained with HE and the tissue lesions were scored according to the histopathological scoring criteria; some organs were stored at -80°C for future use.

[0221] The results of organ coefficients of mice in each group are shown in Table 15.

[0222] Heart coefficient: Compared with the model control group, the heart coefficient of the YSYZ high-dose group was significantly reduced (P < 0.05), and the heart coefficient of the ZDC high-dose group was significantly reduced (P < 0.01).

[0223] Lung coefficient: Compared with the model control group, the lung coefficients of the YSYZ high-dose group and the ZDC high-dose group were significantly reduced (P<0.05).

[0224] There were no statistical differences in the coefficients of other organs.

[0225] Table 15 Organ coefficients of mice in each group (g / kg)

[0226] Group Heart Factor Lung coefficient Liver coefficient Brain coefficient Kidney coefficient Model control group 4.71±0.34 8.17±3.02 64.07±49.29 17.26±1.74 5.90±0.43 YSYZ low dose 4.73±0.33 5.94±1.09 47.01±4.95 17.11±0.48 5.73±0.19 YSYZ High Dose 4.35±0.23* 5.63±0.43* 42.01±1.90 16.98±0.65 5.71±0.15 ZDC low dose group 4.60±0.21 5.80±0.45 46.85±13.72 17.34±1.38 6.10±0.45 ZDC high dose group 4.23±0.34** 5.56±0.52* 46.96±1.80 17.47±0.51 6.08±0.17

[0227] Compared with the model control group, *P<0.05, **P<0.01.

[0228] From the above experimental results, it can be seen that after the natural aging mice were given the Angelica keiskei (n-butanol) extract, the learning and memory ability (short-term memory and long-term memory) of the naturally aging mice was improved, muscle strength and muscle endurance were improved, heat production was increased, energy metabolism was improved, heart function was improved, brain circulation was improved, weakness index was reduced, and hair loss was improved. The Angelica keiskei (n-butanol) extract showed significant anti-aging activity.

[0229] The technical solution of the present invention is not limited to the above-mentioned specific embodiments. All technical variations made according to the technical solution of the present invention fall within the protection scope of the present invention.

Claims

1. An extract of Angelica keiskei, comprising chlorogenic acid, hyperoside and oleuroside.

2. The Angelica keiskei extract according to claim 1, characterized in that In terms of mass percentage, the content of chlorogenic acid is 2.5% to 4.5%, the content of hyperoside is 0.5% to 3.5%, and the content of luteolin is 2.0% to 5.0%; Preferably, in terms of mass percentage, the content of chlorogenic acid is 3.4% to 3.8%, the content of hyperoside is 1.8% to 2.2%, the content of olibanum is 3.6% to 4.2%, the content of 4-hydroxydersin is 0.38% to 0.42%, and the content of yellow angelica alcohol is 0.7% to 0.9%.

3. The Angelica keiskei extract according to claim 1 or 2, characterized in that The Angelica keiskei extract is obtained by a preparation method comprising the following steps: (1) extracting Angelica keiskei with an ethanol solution to obtain an ethanol extract; (2) recovering ethanol from the ethanol extract and concentrating it to obtain a concentrated solution; (3) extracting the concentrated solution with n-butanol to obtain an n-butanol extract.

4. The Angelica keiskei extract according to claim 3, characterized in that The preparation method further comprises: (4) recovering n-butanol from the n-butanol extract and concentrating under reduced pressure to obtain an extract; Optionally, (5) the preparation method further comprises drying the extract to obtain a dry extract; Optionally, (6) the preparation method further comprises crushing the dry paste to obtain dry paste powder.

5. The Angelica keiskei extract according to claim 3 or 4, characterized in that In step (1), the volume concentration of the ethanol solution is 55-65%, preferably 58-62%, more preferably 60%; and / or In step (1), the extraction temperature is such that the ethanol aqueous solution is in a reflux state; and / or In step (1), the extraction is performed 1 to 5 times, preferably 2 to 3 times; and / or In step (1), the extraction time for each extraction is 1 to 3 hours, preferably 1 to 2 hours, more preferably 1.5 hours; and / or In step (1), during each extraction, the mass volume ratio of Angelica keiskei to the ethanol aqueous solution used is 1:5-1:15 (g / mL), more preferably 1:10 (g / mL); and / or In step (2), the content of Angelica keiskei in the concentrated solution is 0.5 to 2 g / ml of the concentrated solution, preferably 0.8 to 1.2 g / ml of the concentrated solution; In step (3), the extraction is performed 1 to 5 times, preferably 2 to 4 times, more preferably 3 times; and / or In step (3), the volume of n-butanol used in each extraction is 0.5 to 3 times, preferably 1 to 1.5 times, the volume of the concentrated solution; and / or In step (4), the volume of n-butanol used for each extraction is 0.5 to 3 times, preferably 1 to 1.5 times, the volume of the concentrated solution; and / or In step (4), the reduced pressure concentration includes first reducing the pressure of the extract to recover n-butanol, and then reducing the pressure of the extract to concentrate at a temperature of 40° C. to 80° C. and a vacuum degree of 0.04 to 0.09 MPa; and / or In step (4), the density of the extract measured at 60° C. is 1.20 to 1.30; and / or In step (5), the extract is dried in a vacuum oven at a drying temperature of 60 to 70° C. and a vacuum degree of 0.04 to 0.1 MPa, preferably 0.04 to 0.08 MPa; the moisture content of the dry extract is controlled to be ≤ 5%; and / or In step (6), the mesh size of the sieve is 80 meshes when the dry paste is crushed and sieved.

6. The Angelica keiskei extract according to any one of claims 2 to 4, characterized in that The preparation method of the Angelica keiskei extract specifically comprises the following steps: a. Place the tomorrow leaf in an extraction tank, add 60% ethanol solution, boil and reflux for 1.5 hours, filter, collect the filtrate, and set aside the residue; b. Add 60% ethanol solution to the residue obtained in step a, boil and reflux for 1.5 hours, filter, collect the filtrate and set aside; c. The filtrate obtained in step a is combined with the filtrate obtained in step b, concentrated under reduced pressure to prepare a concentrate for standby use; d. Add n-butanol to the concentrated solution obtained in step c for extraction, collect the n-butanol extract, extract three times in total, and combine the n-butanol extracts; e. The combined extracts in step d were first decompressed to recover n-butanol, and then concentrated under reduced pressure at a temperature of 40 ℃ to 80 ℃ and a vacuum degree of 0.04 to 0.09 MPa to a relative density of 1.20 to 1.30, measured at 60 ℃ to obtain an extract; f. The extract prepared in step e is dried to obtain a dry paste, which is crushed and sieved to obtain a tomorrow leaf extract.

7. Use of the Angelica keiskei extract according to any one of claims 1 to 6 in the preparation of food for combating natural aging.

8. Use of the Angelica keiskei extract according to any one of claims 1 to 6 in the preparation of a composition for combating natural aging.

9. The use according to claim 7, characterized in that: The food includes common food and health food, and the dosage form of the health food includes capsule, powder, granule, tablet and suspension.

10. The use according to claim 8, characterized in that: The composition contains Angelica keiskei extract, grape seed extract and tomato red microcapsules, and the dosage forms of the composition include capsules, powders, granules, tablets and suspensions.

11. The use according to claim 10, characterized in that: The preparation method of the composition capsule containing Angelica keiskei extract, grape seed extract and tomato red microcapsule comprises: a. The angelica leaf extract, grape seed extract and corn starch were placed in a mixer, the speed was adjusted to 8 rpm, and mixed for example for 30 min to obtain a mixed powder; b. The mixed powder obtained in step a is dry granulated, the main pressure is set to 6 to 10Mpa, through a 14-mesh sieve, the particles are collected and set aside; c. The particles obtained in step b and the tomato red microcapsules and magnesium stearate are placed in a mixer at a speed of 8 rpm and mixed for example for 20 min to obtain a total mixed particle set aside; d. Fill the capsule with the total mixed granules prepared in step c.

12. The use according to claim 7 or 8, characterized in that: The natural aging is manifested as cognitive function decline, and / or muscle strength decline, and / or energy metabolism function decline, and / or heart function decline, and / or cerebral blood flow index decline, and / or weakness index increase, and / or hair decline, and / or organ coefficient increase.